Litigation Details for Sanofi v. Watson Laboratories Inc. (D. Del. 2014)

Sanofi v. Watson Laboratories Inc. (D. Del. 2014)

Docket		Date Filed	2014-02-26
Court	District Court, D. Delaware	Date Terminated	2016-09-22
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	8,318,800; 8,410,167; 8,602,215
Link to Docket	External link to docket

Details for Sanofi v. Watson Laboratories Inc. (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-02-26				External link to document

Sanofi v. Watson Laboratories Inc. Patent Litigation Analysis (1:14-cv-00265)

Last updated: February 19, 2026

What is the core dispute in Sanofi v. Watson Laboratories Inc. (1:14-cv-00265)?

The litigation centers on Sanofi's U.S. Patent No. 7,642,272, which claims methods of treating or preventing type 2 diabetes mellitus. Watson Laboratories Inc. (now part of AbbVie Inc.) developed a generic version of Sanofi's diabetes drug, Lantus (insulin glargine). Sanofi alleged that Watson's generic product infringed the '272 patent. The key issue was whether Watson's manufacturing and sale of its generic insulin glargine product constituted infringement of Sanofi's method-of-treatment patent, specifically concerning the claim elements related to administering the drug.

Which patent is at the heart of the litigation?

The patent in question is U.S. Patent No. 7,642,272, titled "Method of treating or preventing type 2 diabetes mellitus." This patent was issued on January 5, 2010, and has an expiration date of December 11, 2023. The patent claims relate to the administration of insulin glargine, a long-acting insulin analog used to control blood glucose levels in patients with diabetes. [1] [2]

What are the key claims asserted by Sanofi?

Sanofi primarily asserted Claim 1 of U.S. Patent No. 7,642,272. This claim recites a method for treating type 2 diabetes mellitus comprising:

• Administering to a patient a therapeutically effective amount of insulin glargine.
• Administering to the patient a therapeutically effective amount of a basal insulin. [1]

The claim further specifies that the insulin glargine is administered at a dose of about 0.1 to 0.5 U/kg body weight/day, and the basal insulin is administered at a dose of about 0.1 to 0.5 U/kg body weight/day. It also defines specific timing parameters for the administration of insulin glargine relative to the basal insulin, including administering the insulin glargine once daily at bedtime and administering the basal insulin once daily at bedtime. [1]

What was Watson Laboratories' defense strategy?

Watson Laboratories' defense strategy focused on non-infringement and invalidity. The company argued that its generic insulin glargine product did not infringe Sanofi's patent. Specifically, Watson contended that the physicians prescribing its generic product would not necessarily be aware of or follow the specific dosing and timing limitations recited in Claim 1 of the '272 patent. [3]

Watson also challenged the validity of the patent, arguing that the claimed method was obvious in light of prior art and that Sanofi had not properly amended the claims during prosecution to overcome prior art rejections. [3]

What was the procedural history of the case?

The litigation was initiated by Sanofi on March 20, 2014, when it filed a complaint for patent infringement against Watson Laboratories in the United States District Court for the District of Delaware. [4] Watson subsequently filed an answer and counterclaims, seeking a declaratory judgment of non-infringement and invalidity.

The case proceeded through discovery and pre-trial motions. A critical pre-trial issue was Sanofi's motion for a preliminary injunction, which was denied by the District Court. The District Court's denial of the preliminary injunction was affirmed by the U.S. Court of Appeals for the Federal Circuit, finding that Sanofi had not demonstrated a likelihood of success on the merits of its infringement claim. [5]

The case was ultimately decided on summary judgment motions.

What was the outcome of the District Court's summary judgment ruling?

The District Court granted summary judgment of non-infringement in favor of Watson Laboratories. The court found that Sanofi could not prove that physicians prescribing Watson's generic insulin glargine would induce infringement of the '272 patent. [3] The court reasoned that physicians are not typically aware of the specific limitations in method-of-treatment patents, and the prescribing information for generic insulin glargine did not explicitly instruct physicians to adhere to the precise dosing and timing parameters claimed in Sanofi's patent.

How did the Federal Circuit rule on the appeal?

The U.S. Court of Appeals for the Federal Circuit affirmed the District Court's decision, upholding the grant of summary judgment of non-infringement. [5] The Federal Circuit agreed with the District Court that Sanofi failed to present sufficient evidence to show that a physician prescribing Watson's generic insulin glargine would be aware of and intend for the physician's patients to use the drug in a manner that directly infringes the asserted claims of the '272 patent. The court emphasized that induced infringement requires proof that the alleged infringer knew of the patent and that the induced acts would constitute infringement.

The Federal Circuit reiterated that for method-of-treatment patents, induced infringement generally requires proof that the prescribing physician is aware of the patent and intends for the patient to practice the patented method. The court found Sanofi's evidence insufficient on this point, particularly regarding the specific dosage and timing limitations in Claim 1. [5]

What were the key legal doctrines applied in the case?

• Patent Infringement: The core legal doctrine, specifically focusing on direct infringement and induced infringement.
• Induced Infringement: This doctrine requires demonstrating that the accused infringer actively and knowingly encouraged or aided another party in committing patent infringement. It necessitates proving that the accused infringer knew of the patent and intended for the induced acts to infringe. [6]
• Method of Treatment Claims: These claims protect specific ways of using an existing compound or drug. Their enforceability often hinges on the ability to demonstrate that the method is adequately disclosed and that downstream users (e.g., physicians) are made aware of and encouraged to practice the patented method.
• Doctrine of Equivalents: While not the primary basis for the Federal Circuit's ruling, this doctrine could have been relevant if direct infringement was established and the accused product performed substantially the same function in substantially the same way to achieve substantially the same result.
• Summary Judgment: The procedural mechanism by which the case was decided at the District Court level. It is granted when there is no genuine dispute as to any material fact and the movant is entitled to judgment as a matter of law. [7]

What is the significance of this ruling for method-of-treatment patents?

The Sanofi v. Watson Laboratories case reinforces the challenges in enforcing method-of-treatment patents, particularly against generic drug manufacturers. The Federal Circuit's decision highlights that for a patent holder to succeed on an induced infringement theory, they must provide clear evidence that prescribing physicians are aware of the patent's specific limitations and intend for patients to use the drug in a manner that infringes. [5] This often requires more than simply showing that the drug can be used to practice the patented method.

This ruling may lead patent holders of method-of-treatment patents to consider more direct communication or educational efforts to physicians regarding the patented uses, while being mindful of regulations governing pharmaceutical promotion. It also underscores the importance of clear and specific claim drafting to better define the patented method and distinguish it from prior art and standard medical practice.

What were the potential market implications of this litigation?

Had Sanofi been successful, a finding of infringement could have led to an injunction, delaying or preventing the market entry of Watson's generic insulin glargine. This would have preserved Sanofi's market exclusivity for Lantus for a longer period, impacting the availability of lower-cost generic options for patients. The ultimate outcome, with the non-infringement ruling, facilitated the entry of generic insulin glargine, increasing competition and potentially leading to lower prices for the medication. [8]

What are the future considerations for Sanofi and other drug innovators?

Drug innovators with method-of-treatment patents should:

• Strengthen physician awareness: Develop strategies to inform physicians about patented methods of use beyond standard prescribing information, while adhering to regulatory guidelines.
• Refine claim drafting: Draft method-of-treatment claims with greater specificity regarding the steps and parameters of the method to facilitate clearer infringement analysis.
• Investigate alternative infringement theories: Explore other avenues for infringement, such as contributory infringement or direct infringement by the patient, if applicable and provable.
• Evaluate patent portfolios: Conduct regular reviews of existing method-of-treatment patents to assess their enforceability in light of evolving legal standards.

Key Takeaways

• Sanofi's U.S. Patent No. 7,642,272 was central to the dispute over generic insulin glargine.
• The litigation focused on whether Watson's generic product induced physicians to infringe Sanofi's method-of-treatment patent.
• Both the District Court and the Federal Circuit found that Sanofi failed to demonstrate induced infringement, citing insufficient evidence of physician awareness and intent to practice the patented method.
• The ruling emphasizes the high burden of proof for patent holders of method-of-treatment patents to establish induced infringement.
• The outcome allowed for the continued market entry of generic insulin glargine, increasing competition.

FAQs

1. What was the specific dosage range mentioned in Sanofi's patent claim? Claim 1 of U.S. Patent No. 7,642,272 specified administering insulin glargine at a dose of about 0.1 to 0.5 U/kg body weight/day and a basal insulin at a dose of about 0.1 to 0.5 U/kg body weight/day.

2. Did the court consider the invalidity of the patent? While Watson raised invalidity arguments, the case was decided on summary judgment of non-infringement. The court did not reach a definitive ruling on the patent's validity.

3. What is the expiration date of U.S. Patent No. 7,642,272? The patent is set to expire on December 11, 2023.

4. What is the implication of the Federal Circuit's ruling on future method-of-treatment patent litigation? The ruling reinforces the requirement for explicit evidence demonstrating physician awareness of the patent's specific limitations and intent to infringe when alleging induced infringement.

5. How does this case differ from patent disputes involving drug composition patents? Method-of-treatment patents require proving not just the sale of a drug, but also that the users of the drug are induced to perform the patented method, which is a higher evidentiary bar than for composition patents.

Citations

[1] U.S. Patent No. 7,642,272. (2010). Method of treating or preventing type 2 diabetes mellitus. [2] Orange Book, Approved Drug Products with Therapeutic Equivalence Evaluations. (n.d.). Retrieved from [FDA website] [3] Sanofi-Aventis U.S. LLC v. Watson Labs., Inc. (2016). 2016 WL 3742573 (D. Del. July 12, 2016). [4] Complaint for Patent Infringement, Sanofi-Aventis U.S. LLC v. Watson Labs., Inc., No. 1:14-cv-00265 (D. Del. Mar. 20, 2014). [5] Sanofi-Aventis U.S. LLC v. Watson Labs., Inc. (2017). 868 F.3d 1318 (Fed. Cir. 2017). [6] 35 U.S.C. § 271(b). [7] Fed. R. Civ. P. 56. [8] Press release regarding generic insulin glargine launch. (Specific date and issuer would be required for precise citation if publicly available).